The debate between gadolinium versus erythropoietin in a renal transplant patient with nephrogenic systemic fibrosis
In: Journal of Nephrology, Jg. 26 (2012-04-16), S. 48-54
Online
unknown
Zugriff:
Nephrogenic systemic fibrosis (NSF), previously known as nephrogenic fibrosing dermopathy, is a debilitating skin condition that causes fibrotic changes in the set- ting of renal failure. Gadolinium-based contrast agents (GBCA), erythropoietin (EPO), and vascular interven- tion are the most widely known associated factors in the pathogenesis. A 53-year-old female with chronic renal insufficiency secondary to fibrillary glomerulo- nephritis (FGN) presented with generalized hardening of skin 1 week after her renal transplant. Due to her numerous medical and surgical health problems, she had received six imaging procedures with GBCA with the last being eight months prior to the onset of her skin symptoms. She had also historically been treated with high doses of EPO. Histopathologic examination was consistent with NSF. In susceptible renal fail- ure patients who develop NSF after GBCA exposure, the onset of symptoms is usually within a 2-3 month time frame, which undermines but not eliminates the proposed role of GBCA in our patient. It can be pro- posed that despite having various risk factors, while being exposed to high doses of EPO, vascular trau- ma during renal transplant facilitated the onset of her symptoms.
Titel: |
The debate between gadolinium versus erythropoietin in a renal transplant patient with nephrogenic systemic fibrosis
|
---|---|
Autor/in / Beteiligte Person: | Rietkerk, William ; Sina, Bahram ; Safai, Bijan ; Hashemi, Pantea |
Link: | |
Zeitschrift: | Journal of Nephrology, Jg. 26 (2012-04-16), S. 48-54 |
Veröffentlichung: | SAGE Publications, 2012 |
Medientyp: | unknown |
ISSN: | 1121-8428 (print) |
DOI: | 10.5301/jn.5000159 |
Schlagwort: |
|
Sonstiges: |
|